4-HO-MPT

From PsychonautWiki
(Redirected from 4-ho-mpt)
Jump to navigation Jump to search
Summary sheet: 4-HO-MPT
4-HO-MPT
4-HO-MPT.svg
Chemical Nomenclature
Common names 4-HO-MPT, Meprocin
Substitutive name 4-hydroxy-N-methyl-N-propyltryptamine
Systematic name 3-[2-(Methylpropylamino)ethyl]-4-indolol
Class Membership
Psychoactive class Psychedelic
Chemical class Tryptamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 5 mg
Light 10 - 20 mg
Common 20 - 30 mg
Strong 30 - 50 mg
Heavy 50 mg +
Duration
Total 5 - 7 hours
Onset 20 - 60 minutes
Come up 1 - 2 hours
Peak 2 - 3 hours
Offset 1 - 2 hours
After effects 2 - 12 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
Cannabis
Stimulants
Tramadol
Lithium]


4-Hydroxy-N-methyl-N-propyltryptamine (also known as 4-HO-MPT or Meprocin) is a novel synthetic psychedelic substance of the tryptamine chemical class that produces psychedelic effects when administered. It is a closely related structural analog of 4-HO-DMT (Psilocin) and other hallucinogenic tryptamines with powerful psychedelic effects.

Very little data exists about the pharmacological properties, metabolism, and toxicity of 4-HO-MPT. It has been sold online as a research chemical as of 2016.[citation needed] It was synthesised and described by Alexander Shulgin in his 1994 book TiHKAL.[1]

Chemistry

4-HO-MPT, or 4-hydroxy-N,N-methylpropyltryptamine, is a synthetic indole molecule of the tryptamine class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R3 to an amino group via an ethyl side chain. 4-HO-MPT is substituted at R4 of its indole heterocycle with a hydroxyl functional group OH−. It also contains a propyl and ethyl chain bound to the terminal amine RN of its tryptamine backbone (MPT).

Pharmacology

Further information: Serotonergic psychedelic

Like with most psychedelic tryptamines, 4-HO-MPT is thought to act principally as a 5-HT2A partial agonist. The psychedelic effects are believed to come from 4-HO-MPT's binding efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective effects

Metacogghjgjvghnition.png
This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), a literature which relies on collected anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be taken with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses (common+) are more likely to induce the full spectrum of reported effects. Likewise, adverse effects become much more likely with higher doses and may include serious injury or death.

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational 4-HO-MPT use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 4-HO-MPT is a research chemical with very little history of human usage.

Anecdotal evidence from people within the community who have tried it suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

4-HO-MPT is generally considered not habit-forming and the desire to use it can actually decrease with regular consumption. Like with most psychedelics, it is most often thought to be self-regulating.

Tolerance to the effects of 4-HO-MPT are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 4-HO-MPT presents cross-tolerance with all psychedelics, meaning that after the consumption of 4-HO-MPT all psychedelics will have a reduced effect.

Dangerous interactions

Although many psychoactive substances are reasonably safe to use on their own, they can quickly become dangerous or even life-threatening when combined with other substances. The list below includes some known dangerous combinations (although it cannot be guaranteed to include all of them). Independent research (e.g. Google, DuckDuckGo) should always be conducted to ensure that a combination of two or more substances is safe to consume. Some interactions listed have been sourced from TripSit.

  • Lithium - Lithium is commonly prescribed in the treatment of bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
  • Cannabis - Cannabis has an unexpectedly strong and unpredictable synergy with the effects of psychedelics. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid over intake.
  • Stimulants (Amphetamine, cocaine, methylphenidate, ...) - Stimulants affect many parts of the brain and alter dopaminergic function. Combined with psychedelics, stimulation can turn into severe anxiety, panic, thought loops, and paranoia. This interaction may result in an elevated risk of mania and psychosis.[citation needed]
  • Tramadol - Tramadol lowers the seizure threshold[2] and psychedelics may act as triggers for seizures in susceptible individuals.[citation needed]

Legality

Due to its relative obscurity, the possession and sale of 4-HO-MPT is unscheduled in most countries.

  • Germany: 4-HO-MPT is controlled under the NpSG[3] (New Psychoactive Substances Act) as of July 18, 2019.[4] Production and import with the aim to place it on the market, administration to another person, placing it on the market and trading is punishable. Possession is illegal but not punishable.[5][6] The legislator considers it possible that orders of 4-HO-MPT are punishable as an incitement to place it on the market.[7]
  • Switzerland: 4-HO-MPT is not controlled under Buchstabe A, B, C and D. It could be considered legal.[8]
  • United Kingdom: 4-HO-MPT is a Class A drug in the United Kingdom as a result of the tryptamine catch-all clause.[9]
  • United States: 4-HO-MPT is unscheduled in the United States. It may be considered an analogue of psilocin (4-HO-DMT) which is a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.[citation needed]

See also

External links

References

  1. Shulgin, Alexander; Shulgin, Ann (1997). "#23. 4-HO-MPT". TiHKAL: The Continuation. United States: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252. 
  2. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039. 
  3. "Anlage NpSG" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  4. "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. ISSN 0341-1095. 
  5. "§ 4 NpSG" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  6. "§ 3 NpSG" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  7. "Gesetzentwurf der Bundesregierung: Entwurf eines Gesetzes zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe" (PDF) (in German). Deutscher Bundestag. May 30, 2016. p. 20. Drucksache 18/8579. 
  8. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  9. "Schedule 2: Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved August 20, 2020.